Acumen Pharmaceuticals, Inc. ABOS

NEWTON, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that the Company will host a virtual Investor Day on Wednesday, September 16, 2026 at 10:00 a.m. ET. To participate in the live conference call, please register using this link. After registration

NEWTON, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in the following upcoming investor conferences. Cantor Global Healthcare Conference 2026 Date/Time: Fireside chat on Wednesday, September 9, 2026 at 3:55 p.m. ET Citi’s 2026 Biopharma Back to

Acumen Pharmaceuticals Inc (ABOS) reports strong progress on its lead Alzheimer's candidate and next-generation pipeline, with cash runway into early 2027.

Moby summary of Acumen Pharmaceuticals, Inc.'s Q2 2026 earnings call

Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026Two candidates nominated for development in Acumen’s Enhanced Brain Delivery™ (EBD™) program; lead clinical candidate IND filing for the EBD program targeted for mid-2027Cash, cash equivalents and marketable securities of $110.2 million as of June 30, 2026, expected to support current clinical and operational activities into early 2027Co

NEWTON, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report second quarter financial results on Wednesday, Aug. 12, 2026. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and fi

By Daniella Parra VERAXA Biotech said it received positive scientific advice from Germany’s Paul-Ehrlich-Institute supporting a preclinical development plan for its experimental BiTAC-TCE cancer therapy platform. The feedback provides greater regulatory clarity and reduces some early-stage development risk as the company advances its lead candidate toward clinical trials, it said. READ MORE The Cancer […] The post VERAXA Biotech Shows Regulatory Progress on Cancer Therapy Platform appeared first

By Daniella Parra Slate Medicines, a private biotech company developing new treatments for migraine and other headache disorders, has appointed Mark W. Hahn to its Board of Directors, they said. The company said Hahn brings more than 25 years of life sciences leadership experience, including serving as CFO of Verona Pharma, where he helped guide […] The post Slate Medicines Appoints Mark W. Hahn to Board of Directors appeared first on ExecEdge.

EBD™ bispecific antibodies targeting both AβOs and hTfR showed improved brain penetration compared to the native anti-AβO antibodies, which may enable administration with a low-volume delivery device and reduce the delivered dose required for efficacyEBD candidate ACU401 achieves up to 40-fold greater frontal cortex exposure in non-human primates and significant increase in exposures in deep brain regionsNo hematological safety signals observed in non-human primates, demonstrating low potential

SAN FRANCISCO, CA AND NEWTON, MA / ACCESS Newswire / July 9, 2026 / Unlearn, a pioneer of AI-powered solutions for clinical development, today announced a collaboration with Acumen Pharmaceuticals (Acumen), a clinical-stage biopharmaceutical company ...

NEWTON, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), will present three key studies at the upcoming Alzheimer's Association International Conference (AAIC®) 2026 in London. Shared in one oral and two poster presentations, the data highlight Acumen’s progress with JCR Pharmaceutic

HYOGO, Japan, June 17, 2026--Acumen exercised its option to develop, manufacture, & commercialize, on a global basis, up to two candidates for development in the treatment of AD.

Moby summary of Acumen Pharmaceuticals, Inc.'s Q1 2026 earnings call